What is it about?
Currently, the development of antifactor VIII (FVIII) inhibitors is the most serious treatment-related complication for haemophilia A patients. Inhibitor development is still considered a poorly predictable multifactorial event, including both genetic and environmental risk factors, the later including certain vaccines. In this sense, it has been postulated that simultaneous vaccine administration and FVIII infusion could be perceived by the immune system as ‘danger signals’ and subsequently, it would promote the development of inhibitors; nevertheless, there are no available evidences in the literature showing a link between the formation of inhibitors and the desensitizing therapy commonly used in allergic patients.
The following have contributed to this page: Dr Nuria Bermejo
In partnership with: